Nodular disease is a granulomatous inflammation, and the latest treatments include anti-tumor necrosis factor-α, B-cell ablative therapy, mesenchymal stem cell therapy, interleukin-6 inhibitors, PD-1/PD-1 inhibitors, and endothelin receptor antagonists. 1. Anti-tumor necrosis factor-α: such as infliximab. Because tumor necrosis factor-α is a key cytokine in the formation and maintenance of granulomas. 2. B-cell ablation therapy: nodular disease is mainly a T-cell immune-mediated disease. Some studies have shown that B cells also have a pathogenic role and that B cell activation factor (BAFF) levels correlate with nodule activity and severity. Treatment with B-cell ablation results in B-cell depletion and normalization of BAFF levels. 3. Mesenchymal stem cell therapies (MSCs): MSCs can alter the activation and proliferation of T-cells and have an immunomodulatory effect on B-cells. 4. Interleukin-6 (IL-6) inhibitors: such as tolizumab, which can effectively antagonize the IL-6 receptor and inhibit T cell proliferation and differentiation. 5. PD-1 inhibitors: the high expression of PD-1 will reduce the proliferation of T cells, inhibition of PD-1 can restore the proliferation of T cells and immune function. normalization of T cell function is an important factor in the natural remission of nodular disease. 6. Endothelin (ET-1) receptor antagonist: It can induce the differentiation of lung fibers to myofibroblasts and produce too many components involved in pulmonary fibrosis. Therefore, endothelin receptor antagonists, such as bosentan, are anti-fibrotic. All of the above medications should be used under the supervision of a physician. If the disease is diagnosed, please go to the hospital for standardized treatment.